Progressive Supranuclear Palsy Pathophysiology
Progressive supranuclear palsy is fundamentally a tauopathy characterized by abnormal accumulation of hyperphosphorylated tau protein in neurons and glial cells, primarily affecting the basal ganglia, brainstem, and cerebellum, leading to neurodegeneration and clinical manifestations. 1
Core Pathological Mechanism
PSP belongs to the "Parkinson-plus" syndromes and is distinguished from Parkinson's disease by its underlying protein pathology. While Parkinson's disease is a synucleinopathy with Lewy body deposits, PSP is a tauopathy where tau proteins abnormally accumulate in different brain regions 1. This is a critical distinction that fundamentally separates PSP from other parkinsonian disorders.
Molecular Pathology
The disease process centers on microtubule-associated protein tau (MAPT), which becomes hyperphosphorylated and forms neurofibrillary tangles 2, 3. These tau deposits accumulate specifically in:
- Subthalamic nucleus
- Pallidum
- Red nucleus
- Substantia nigra (with loss of pigment corresponding to nigrostriatal dopaminergic degeneration)
- Striatum
- Pontine tegmentum
- Oculomotor nucleus
- Medulla
- Dentate nucleus
- Midbrain tectum
- Superior cerebellar peduncle 4, 3
The characteristic feature distinguishing PSP from other tauopathies is that tau pathology affects both neurons AND glial cells 3, creating a more widespread pattern of dysfunction.
Genetic and Environmental Factors
The major genetic risk factor is a common variant in the MAPT gene itself, which may alter the expression of specific tau protein isoforms 3. This genetic predisposition interacts with environmental factors including:
- Oxidative damage and mitochondrial dysfunction 2, 5
- Neurotoxins (dietary and environmental)
- Industrial pollutants 6
- The MAPT H1 haplotype shows regional variation in prevalence 6
Neurodegenerative Process
The pathological cascade results in:
- Neuronal loss and gliosis in the affected regions 2, 3
- Disruption of microtubule dynamics and axonal transport due to tau accumulation 7
- Dysfunction of multiple neurotransmitter systems:
Structural Changes
Macroscopic atrophy is prominent in the subthalamic nucleus and brainstem, especially the midbrain tectum and superior cerebellar peduncle 3. The substantia nigra shows loss of pigment reflecting nigrostriatal dopaminergic degeneration 3.
Metabolic Patterns
FDG-PET demonstrates a characteristic pattern: hypometabolism in the medial frontal and anterior cingulate cortices, striatum, and midbrain 1. This metabolic signature helps differentiate PSP from idiopathic Parkinson's disease.
Clinical-Pathological Correlation
The pathological distribution directly explains clinical features:
- Vertical supranuclear gaze palsy: Oculomotor nucleus and midbrain tegmentum involvement
- Postural instability and falls: Basal ganglia, brainstem, and cerebellar degeneration with cholinergic denervation 8
- Axial rigidity: Extrapyramidal system degeneration
- Cognitive impairment/dementia: Frontal cortex tau accumulation and subcortical-cortical disconnection 7
- Pseudobulbar palsy: Brainstem involvement
Important Caveats
Isolated PSP neuropathology is uncommon—nearly 70% of cases show co-pathologies including Alzheimer-type changes, Lewy bodies, TDP-43 pathology, and argyrophilic grains 9. This complicates the pure pathophysiological picture and may influence clinical presentation and progression.
The disease represents a dynamic process where pathological events develop at different rates, leading to different clinical phenotypes (PSP-RS, PSP-P, PSP-PGF, PSP-CBS) 10, 6. The rate and regional distribution of tau accumulation determines which clinical syndrome emerges.
The primary initiating cause remains unknown 5, though the convergence of genetic susceptibility (MAPT variants), environmental factors, and age-related cellular vulnerability appears necessary for disease development.